Celularity to provide research support for Regeneron’s targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy
Agreement underscores Celularity’s demonstrated expertise in cell therapy research. (Credit: ajay_suresh from Wikimedia Commons)
Celularity, a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals to support the research of Regeneron’s allogeneic cell therapy candidates.
The agreement’s initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. The research will take place at Celularity’s state-of-the-art facility located in Florham Park, N.J. Financial terms were not disclosed.
“The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. We believe that this relationship paves the way for future industry collaborations leveraging our world class cell therapy facilities and capabilities,” said Robert J. Hariri, M.D., Ph.D., Celularity’s CEO, Chairman and Founder. “We have long admired the exceptional scientific legacy at Regeneron and welcome the opportunity to collaborate with a world leader in innovative medicines.”
Source: Company Press Release